Market Overview

Quanta to Participate in Upcoming Virtual Investor Conferences


ALCESTER, United Kingdom, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a British medical technology innovation company, today announces that management will be participating in three upcoming investor conferences.

Details of the virtual conferences are as follows:

Jefferies London Healthcare Conference, November 17-19, 2020
Date: Wednesday, November 18
Time: 10:35am GMT/5:35am EST

Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum, November 19, 2020
Date: Thursday, November 19
Time: 1:30pm GMT/8:30am EST

Piper Sandler 32nd Annual Healthcare Conference, November 30 - December 3, 2020
Management will participate in investor 1x1 meetings on Monday, November 30, 2020.

For more information about Quanta, please contact:

John E. Milad,
Chief Executive Officer

T: +44 (0)1789 400043
Consilium Strategic Communications
Amber Fennell / Matthew Neal / Lindsey Neville
T: +44 (0)203 709 5708

About Quanta and SC+
Based in the Midlands of the UK, Quanta is a technology-enabled provider of innovative dialysis products and services. Quanta aims at improving dialysis experiences and helping people to live more freely. The lead product SC+ is a small, simple and versatile haemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments — making the therapy manageable to a broad range of users across a wide range of environments, from the ICU to the home.

SC+ is CE Marked and commercially available in the UK, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The unobtrusive, simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

For more information, please visit our website:

SC+ is not yet FDA cleared and not yet available for sale or use in the USA.

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at